通过孟德尔随机化揭示PRKCD是有前途的治疗目标
Jie Zhou1,2, Yixin Xu1,2, Haitao Wang3
1Department of Gastrointestinal Surgery, The Wujin Hospital Affiliated with Jiangsu University, Changzhou, China.
Endocrine, metabolic & immune disorders drug targets
|September 5, 2025
概括
研究人员确定了18个可用药物治疗的基因与腹腔疾病 (CeD) 有因果关系. 该PRKCD基因显示为CeD治疗的新型治疗点,解决了一个关键的未满足的医疗需求.
科学领域:
- 遗传学
- 免疫学
- 药理学
背景情况:
- 乳病是一种严重的自身免疫性疾病,需要有效的药物治疗.
- 目前的治疗依赖于严格的无质饮食,
研究的目的:
- 使用遗传关联数据识别与腹腔疾病 (CeD) 有因果关系的可用药物基因.
- 通过分析大规模的遗传联盟数据,确定CeD的新疗法目标.
主要方法:
- 来自eQTLGen和FinnGen联盟的CeD总结统计数据的孟德尔随机化 (MR) 分析.
- 使用反变量加权 (IVW) 方法识别了CeD相关的基因,错误发现率 (FDR) < 0.05.
- 通过局部化分析和基于总结数据的门德尔随机化 (SMR) 分析验证的结果.
主要成果:
- 鉴定了与CeD因果相关的18个可用药物的基因 (FDR < 0.05).
- 该PRKCD基因被认为是CeD的重要潜在治疗标 (OR 1.319,P = 6. 85E-07,FDR = 0. 002).
- 结果是强大的,通过了多样性,异质性和灵敏性分析.
结论:
- 这项研究首次确定了PRKCD基因作为CeD的潜在治疗点.
- 这些发现为CeD病变提供了新的见解,并指导了新药治疗的开发.
- 需要进一步实验验证PRKCD在CeD中的作用及其治疗潜力.
相关概念视频
In-vitro Mutagenesis
14.8K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.8K
M-Cdk Drives Transition Into Mitosis
5.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119


